Creo Medical Group (AIM:CREO) told investors that its MicroBlate Flex microwave ablation product has now been used in more than 100 clinical cases.
The AIM-listed company develops minimally invasive surgical endoscopy devices for pre-cancer and cancer patients, and it expects case numbers to rise rapidly over the next 12 months as the product remains in the early stages of its rollout.
MicroBlate Flex is a flexible endoscopic device designed to deliver precise microwave ablation to nodules and tumours, including hard-to-reach lung lesions.
The growing case volume feeds into Creo's long-term collaboration with Intuitive Surgical, which combines robotic-assisted navigation with flexible microwave ablation to build real-world experience in lung tumour treatment pathways.
Professor Pallav Shar, a consultant respiratory physician at Guy's and St Thomas' NHS Foundation Trust, said the robotic-assisted bronchoscopy approach with MicroBlate Flex "broadens treatment options, particularly for patients with severe lung disease who may not have any other treatment options".
Chief executive Craig Gulliford said the milestone reflects growing clinician engagement and real-world momentum as physicians gain experience with the device.
He added that the accumulating clinical evidence, workflow development and health economics data would support broader adoption as earlier lung cancer diagnosis rates increase demand for precise, minimally invasive treatment options.
News Intelligence what this means for the company
Creo Medical's MicroBlate Flex microwave ablation device has reached 100 clinical cases, signalling early traction in a market for minimally invasive lung tumour treatment. The milestone matters because the company is still in early rollout and expects case volumes to accelerate over the next 12 months; the collaboration with Intuitive Surgical on robotic-assisted navigation adds a pathway to broader adoption as clinicians accumulate real-world evidence and health economics data.
- Intuitive Surgical gains clinical validation data from the MicroBlate Flex partnership, supporting the robotic-assisted bronchoscopy workflow development.
The 100-case milestone reinforces that MicroBlate Flex is moving from concept to clinical adoption, but the company remains in early commercialisation. Real-world case accumulation and health economics evidence will be critical to justify the broader adoption the CEO expects as lung cancer diagnosis rates rise; execution risks remain.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
Shore Capital sets 40p fair value on Creo Medical
Shore Capital's Dr Sean Conroy, in a note, said the 100-case milestone supports his adoption thesis and assigns a House Stock rating with a 40p fair value. The analyst highlights a potential regulatory pathway in 2027 as the key near-term catalyst for broader commercial rollout with Intuitive Surgical.
He also noted that early clinical data show favourable tolerability and recurrence rates comparable to radiotherapy, reinforcing the commercial case.
